Voronoi, Inc. researches, develops, and discovers small molecule kinase inhibitors in South Korea. Its products pipeline includes VRN01, an oral leucine rich repeat kinase 2 inhibitor targeting glioblastoma multiforme to treat brain and pancreatic cancers; VRN07, VRN06, and VRN11 for the treatment of lung cancer; VRN08 and VRN10 to treat breast cancer; and VRN02 for the treatment of rheumatoid arthritis and atopic dermatitis. The company's products pipeline also comprise VRN04-1 to treat autoimmune diseases; VRN04-2 for the treatment of multiple sclerosis and amyotrophic lateral sclerosis; VRN13 to treat pulmonary arterial hypertension; and VRN14 for the treatment of refractory solid cancer. Voronoi, Inc. was incorporated in 2015 and is based in Incheon, South Korea.
Frequently asked questions
What sector does Voronoi Co. Ltd. (310210) operate in?
Voronoi Co. Ltd. belongs to the Energy sector and operates in the Biotechnology industry.
What is Voronoi Co. Ltd. (310210) current stock price?
As of the latest data, Voronoi Co. Ltd. stock price is ₩180,700, with a previous close of ₩180,700.
What is Voronoi Co. Ltd. (310210) current market capitalization?
Voronoi Co. Ltd. market cap is approximately 3.31 trillion.
Does Voronoi Co. Ltd. (310210) pay dividends?
No. Voronoi Co. Ltd. does not pay a dividend.
What is Voronoi Co. Ltd. (310210) beta (volatility) score?
Voronoi Co. Ltd. has a beta of 1.477, suggesting it is more volatile than the market.
